Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus Vaccine in Healthy Female Children
by on Tuesday, June 26th, 2012 | No Comments
Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia
Interventions: Biological: Cervarix; Biological: MMR; Biological: DTPa
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting – verified June 2012
Go here to see the original: Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus Vaccine in Healthy Female Children